GrandPharm obtained the right to commercialize BRM421,a new drug for dry eye syndrome, in mainland China, HK and Macau.
|Description||GrandPharm obtained the right to develop and commercialize BRM421 in greater China. At the same time, GrandPharm subscribed for a small amount of equity of Brimbiotech|
|Global M&A Offices||
Hollyhigh International Capital (Global M&A China)
|Global M&A Advisory||Advisor to the seller|
|Further information||For further details, see: https://www.brimbiotech.com/en/brm421/ and http://www.grandpharma.cn/en/AboutUs/about.aspx|